AI upstart grabs $40M launch round; Sanofi backs a gene therapy player; Axsome hits a snag at the FDA
Boston AI-focused biotech DeepCure closed a $40 million Series A, according to a company announcement this morning — adding more than five …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
